BETWEEN IMMUNOCORE LIMITED. on the one hand, AND GENENTECH, INC AND on the other hand, AS OF JUNE 14, 2013Collaboration Agreement • December 22nd, 2020 • Immunocore LTD • Biological products, (no disgnostic substances) • England and Wales
Contract Type FiledDecember 22nd, 2020 Company Industry JurisdictionThis Research Collaboration and License Agreement (“Agreement”) is made and entered into, effective as of June 14, 2013 (“Effective Date”), by and between Immunocore Limited, having its principal place of business at 57 Jubilee Avenue, Milton Park, Abingdon, Oxon, United Kingdom OX14 4RX (“Immunocore”), on the other hand, Genentech, Inc., a Delaware corporation, having its principal place of business at 1 DNA Way, South San Francisco, California 94080 (“GNE”) and F. Hoffmann-La Roche Ltd, with its principal place of business at Grenzacherstrasse 124, CH 4070 Basel, Switzerland (“Roche”), on the other hand. GNE and Immunocore are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” The term “Party” or “Parties” shall not include Roche unless explicitly stated below.